Beyond Self-Monitored Plasma Glucose and HbA1c: the Role of Non-Traditional Glycaemic Markers in Gestational Diabetes Mellitus by Mendes, N et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ijog20
Journal of Obstetrics and Gynaecology
ISSN: 0144-3615 (Print) 1364-6893 (Online) Journal homepage: http://www.tandfonline.com/loi/ijog20
Beyond self-monitored plasma glucose and HbA1c:
the role of non-traditional glycaemic markers in
gestational diabetes mellitus
Neuza Mendes, Rogério Tavares Ribeiro & Fátima Serrano
To cite this article: Neuza Mendes, Rogério Tavares Ribeiro & Fátima Serrano (2018):
Beyond self-monitored plasma glucose and HbA1c: the role of non-traditional glycaemic
markers in gestational diabetes mellitus, Journal of Obstetrics and Gynaecology, DOI:
10.1080/01443615.2017.1412409
To link to this article:  https://doi.org/10.1080/01443615.2017.1412409
Published online: 05 Apr 2018.
Submit your article to this journal 
View related articles 
View Crossmark data
REVIEW ARTICLE
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aDepartment of Maternal-Fetal Medicine, Maternidade Dr. Alfredo da Costa, Central Lisbon Hospital Center, Lisbon, Portugal; bNOVA Medical
School, Universidade NOVA de Lisboa, Lisbon, Portugal; cEducation and Research Center (APDP-ERC), Portuguese Diabetes Association,
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ABSTRACT
Strict glycaemic management is the cornerstone of metabolic control in gestational diabetes mellitus
(GDM). Current monitoring standards involve self-monitoring plasma glucose (SMBG) and haemoglobin
A1c (HbA1c). However, both have important limitations. SMBG only reflects instantaneous blood glu-
cose and the inconvenience of self-collecting blood frequently results in poor compliance. HbA1c
provides information on blood glucose levels from the previous 2 to 3months and it is influenced by
iron-deficient states, common during pregnancy. There is an urgent need for new shorter-term gly-
caemic markers, as glycated albumin, fructosamine or 1,5-anhydroglucitol. Glycated albumin seems
especially interesting as it provides information on blood glucose levels over the foregoing 2–3weeks
and it is not influenced by iron deficiency or the dilutional anaemia of pregnancy. Fructosamine has a
precise and inexpensive measurement and it is not affected by haemoglobin characteristics. This review
further discusses the potential value of these non-traditional indicators of glycaemic control in patients








Gestational diabetes mellitus (GDM) is a condition in women
who have glucose intolerance with onset or recognition dur-
ing pregnancy (Metzger and Coustan 1998; American College
of Obstetricians and Gynecologists (ACOG) 2013; American
Diabetes Association 2015). It has been steadily increasing
since the 1990s (National Institutes of Health 2013). This is
partly due to changes in its diagnostic criteria, but mostly
because of changes in its known risk factors, as an advanced
maternal age, higher body mass index, and racial and ethnic
demography (International Diabetes Federation 2015;
NICE Guideline 2015). In 2015, the International Diabetes
Federation estimated GDM to affect approximately one in
25 pregnancies worldwide (International Diabetes Federation
2015).
Women with GDM are at higher risk of gestational hyper-
tension, preeclampsia, caesarean delivery, and its associated
potential morbidities and, most importantly, of developing
diabetes later in life (Yogev et al. 2004; Bellamy et al. 2009;
American College of Obstetricians and Gynecologists (ACOG)
2013). Adverse neonatal effects include macrosomia, opera-
tive delivery, shoulder dystocia, birth trauma, respiratory dis-
tress syndrome, myocardial hypertrophy, hypoglycaemia,
hypocalcaemia, polycythaemia and hyperbilirubinemia
(Metzger et al. 2008; International Diabetes Federation 2015;
American College of Obstetricians and Gynecologists (ACOG)
2013; NICE Guideline 2015). Long-term effects, diabetes melli-
tus and metabolic syndrome, have been actively discussed.
Most of these perinatal maternal–infant complications can
be prevented by an early detection of abnormal maternal
glucose tolerance and good glycaemic control during preg-
nancy (Evers et al. 2002; Lauenborg et al. 2003).
The lack of international uniformity in the approach to
ascertainment, diagnosis and management of GDM has been a
major hurdle (Table 1). Nevertheless, most authors agree that
the aims in GDM include (1) prevention of short-term perinatal
complications in mothers and foetuses/neonates; (2) preven-
tion of long-term adverse health outcomes in both mothers
and their offspring. To meet these goals, universal timely
screening for GDM, strict glycaemic control during pregnancy
and rescreening revaluation and follow-up during the puerper-
ium are of great importance (Kitzmiller et al. 1996; Hiramatsu
et al. 2012). The prospective Hyperglycaemia and Adverse
Pregnancy Outcome (HAPO) study revealed a continuous rela-
tionship between mild maternal hyperglycaemia at
24–32weeks and adverse perinatal outcomes, highlighting
even more the importance of attaining excellent glycaemic
control during pregnancy (Metzger et al. 2008). Plasma glu-
cose measurement is of great importance, but it is actually not
possible to measure in all patients and it has limitations.
HbA1c is currently the most widely used indicator of
glycaemic control in clinical practice. However, there is a grow-
ing interest in the serum biomarkers of hyperglycaemia, such
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as fructosamine, glycated albumin (GA) and 1,5-anhydrogluci-
tol (1,5-AG). Here, we will try to uncover their potential advan-
tages and limitations in the management of GDM (Table 2).
Indicators of glycaemic control
The gold of glycaemic control during pregnancy is to bring
plasma glucose level as close to normal as possible without
the development of hypoglycaemia. The current monitoring
standard for GDM involves self-monitoring of plasma glucose
(SMBG). Continuous glucose monitoring is able to improve
glycaemic control during the third trimester of pregnancy,
and to decrease the risk of macrosomia (Murphy et al. 2008)
in pregnant women with pregestational type 1 diabetes, but
its potential use in GDM awaits further data and cost-effect-
iveness analysis. It has a high cost and needs to be per-
formed by a healthcare professional.
SMBG enables strict glycaemic control. It also allows
patients to understand the relationship between meals,
snacks, events, activity and blood glucose levels. When insulin
therapy is needed, its adjustments according to SMBG have
demonstrated value in decreasing macrosomia, neonatal
hypoglycaemia and caesarean section (Langer et al. 1989,
1991; De Veciana et al. 1995). However, it only reflects
instantaneous blood glucose, which is susceptible to factors
such as emotion or diet and provides no assessment on
chronic or mean glycaemic levels. Furthermore, the pain and
inconvenience of collecting blood from a finger (in most set-
tings six times daily), frequently result in poor compliance.
Therefore, SMBG is an important part of current manage-
ment of GDM but has limitations and does not substitute the
information given by indicators of glycaemic control.
Haemoglobin A1c (HbA1c)
Amongst the glycated proteins known to be of interest in
diabetes, Hb A1c was identified more than 40 years ago. It is
currently in wide use as the standard marker for clinical man-
agement of diabetes. Besides its diagnostic value, it provides
a reliable assessment of chronic glycaemic levels that are
intimately related to the risk of diabetic complications. In red
blood cells, HbA1c is haemoglobin that has glucose attached
to the N-terminal valine of the beta chain, and is reported as
a proportion of total haemoglobin. Because the lifespan of
red blood cells is approximately 120 days, HbA1c, therefore,
reflects average glycaemia over the past 1–4months – Tahara
Table 1. Screening and diagnosis guidelines from different associations.





IADPSG All women “One-step” 75 g OGTT N/A N/A Fasting 5.1
1 h 10.0
2 h 8.5
1 level must be met
IDF All women “One–step“ 75 g OGTT N/A N/A Fasting 5.1
1 h 10.0
2h 8.5
1 level must be met
ADA All women “One-step“ 75 g OGTT N/A N/A Fasting 5.1
1 h 10.0
2h 8.5
1 level must be met
CDA All women 50 g GCT (preferred)
Alternative: “one-step”
75 g OGTT
7.8 75g OGTT (a) 11.1 on 50 g GCT




1 level must be met
NICE Women with risk factors Risk factorsb N/A 75 g OGTT Fasting 7.0
2 h 7.8
1 level must be met
ACOG All women 50 g GCT 135 or 7.8a 100 g OGTT (a) Fasting 5.3
1 h 10.0
2 h  8.6
3 h  7.8 ora
(b) Fasting 5.8
1 h 10.6
2 h  9.2
3 h  8.0
2 levels must be met
WHO (a) Women with risk factors
(b) All women
(a) Risk factorsc
(b) ”One-step” 75g OGTT
N/A 75g OGTT Fasting 7.0
2 h 7.8
1 level must be met
ACOG: American College of Obtetricians and Gynecologists; ADA: American Diabetes Association; CDA: Canadian Diabetes Association; GCT: Glucose challenge test;
IADPSG: International Association of Diabetes and Pregnancy Study Group; IDF: International Diabetes Federation; NICE: National Institute for Health and Care
Excellence; OGTT: Glucose tolerance test; WHO: World Health Organisation.
aIt is suggested that practitioners and institutions should select a single set of screening and diagnostic criteria for consistent use within their patient
populations.
bPrevious baby weighting 4.5 kg, previous GDM, first-degree relative with diabetes, family origin with a high prevalence of diabetes, body mass index
>30 kg/m2.
cOlder women, obese women, previous history of glucose intolerance, history of GDM, pregnant women with elevated fasting or casual blood glucose levels, pre-
vious macrosomic baby, strong family history of diabetes, women from high-risk ethnic groups.
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and Shima (1995) reported that 50% reflect plasma glucose
level during the past 1month, 25% reflect plasma glucose
level during the past 1–2months, and another 25% reflect
plasma glucose level during the past 2–4months. In addition,
as pregnancy progresses, insulin resistance rapidly increases
and glucose tolerance changes. So, during pregnancy, a
marker that reflects glycaemic control status mostly in the
previous 2–3months may become of limited value.
The correlation of HbA1c with microvascular and macro-
vascular complications of diabetes is well known. However,
pregnant women are usually excluded from these clinical
studies, and chronic diabetic complications usually do not
develop within a period as short as the few months of GDM.
It has been reported that in non-diabetic pregnant
women the time course of HbA1c is characterised by a
biphasic change with the trough level occurring at week 24
of pregnancy: HbA1c tends to decrease during the middle
stage and increase during the end stage of pregnancy
(Phelps et al. 1983; Worth et al. 1985; Hiramatsu et al.
2012). In a study conducted by Nielsen et al. (2004), how-
ever, HbA1c levels began to decline from early pregnancy
and further decreased in late pregnancy. These changes are
likely a mix between several sources of interference related
with pregnancy.
Disadvantages of HbA1c include limited interpretability in
the setting of abnormal erythrocyte altered lifespan (Panzer
et al. 1982). In patients with iron deficiency anaemia, HbA1c
is known to be elevated and it has already been demon-
strated that HbA1c levels are also elevated in iron deficiency
states without anaemia (Koga et al. 2007). When investigating
the effect of iron deficiency on HbA1c in 47 non-diabetic
Japanese pregnant women, the group of Hashimoto (2008)
found that in normal pregnant women, iron deficiency pro-
gresses during the end stage of pregnancy and that there is
a significant negative correlation between HbA1c and serum
ferritin, transferring saturation and mean corpuscular haemo-
globin. Therefore, in non-diabetic pregnant women, at the
end-stage of pregnancy, as iron deficiency progresses, HbA1c
increases. It is not known if iron supplementation during
pregnancy is able to neutralise this phenomenon. Hashimoto
et al. (2010) further conducted a longitudinal study in 17
pregnant Japanese women with diabetes (six with GDM) and
found that HbA1c levels are also higher relative to plasma
glucose level during the end stage of diabetic pregnancies,
during which most women are iron deficient. Other factors
that can modify HbA1c independent of the true level of gly-
caemia, studied outside the context of pregnancy, comprise
cigarette smoking, consumption of alcohol and dietary fat,
advanced kidney and liver disease, age and ethnic origin
(Cohen and Herman 2014). In a very recent multicentre study
aimed to identify the determinants of HbA1c in subjects with
impaired glucose tolerance (Sakane et al. 2017), BMI was cor-
related with higher HbA1c in a multiple regression analysis.
In pregnancy, few data exists, and to our knowledge, none in
women with GDM. Nonetheless, in the study conducted by
the Japan GA Study Group involving 574 healthy Japanese
pregnant women that analysed GA and HbA1c influencing
factors during pregnancy, HbA1 levels were higher in the
obese group (18.5 BMI <25 kg/m2) than those in of the
control group (Hiramatsu et al. 2012).




HbA1c Proportion of haemoglobin that
is glycated
1–4 months Low within-person variability;
extensive experience in pre-
gestational diabetes; readily
available in most settings
Affected by alterations in red cell
turnover; inaccurate results in the
presence of certain haemoglobin
variants with some methods of
measurement; affected by iron defi-
ciency states with and without
anaemia in pregnant women with
diabetes (pregestational and GDM);
limited evidence linking to out-
comes in GDM
Glycated albumin Proportion of albumin that is
glycated
2–3 weeks Not affected by iron deficient
states or iron deficiency
anaemia (pregestational dia-
betes and GDM); not affected
by dilutional anaemia of
pregnancy
Influenced by conditions that interfere
with albumin metabolism, as neph-
rotic syndrome or abnormal thyroid
function; lacks widely accepted ref-
erence interval; limited evidence
linking to outcomes; not available
in many settings; method perform-
ance may vary
Fructosamine Total serum protein glycation 2–4 weeks Not affected by haemoglobin
characteristics; not influenced




Affected by dilutional anaemia; influ-
enced by conditions that interfere
with albumin metabolism, as neph-
rotic syndrome or abnormal thyroid
function; limited evidence linking
to outcomes
1.5-Anhydroglucitrol Monosaccharide filtered by the
kidney and normally reab-
sorbed, when glycaemia
exceeds the renal threshold
(± 180mg/dL), glucose com-
petes with 1.5 AG for reab-
sortion, 1.5 AG is excreted in
the urine, so serum levels
drop
2–14 d Tests readily available Affected by the changes in renal
threshold for glucose induced by
pregnancy; limited evidence linking
to outcomes
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Glycated albumin (GA)
GA is a ketoamine formed from a non-enzymatic reaction
and binding between four lysine residues of albumin and glu-
cose. It is an amadori compound, as is HbA1c, but albumin is
reported to be approximately 10 times more sensitive to gly-
cation than haemoglobin (Arasteh et al. 2014). Because the
half-life of albumin is about 14 days, GA measurements are
representatives of a far shorter period of exposure to circulat-
ing glucose than HbA1c, about 2–3weeks (Koga and
Kasayama 2010). Thus, GA is a better index of short-term gly-
caemic control than HbA1c. This may be of great interest in
GDM, as metabolic alterations are far more dynamic than the
prior 2–3months assessed by HbA1c. Previous studies have
shown that this glycaemic marker has a higher sensitivity to
glycaemic fluctuations than HbA1c, and provides useful infor-
mation in evaluating blood glucose in diabetic patients (Abe
et al. 1993; Koga et al. 2006; Yoshiuchi et al. 2008). A study
by Pan et al. (2013) which enrolled 713 pregnant women
with abnormal 50 g GCT, showed that compared with HbA1c,
GA is more closely correlated with fasting and postprandial
glucose, regardless of insulin resistance and blood pressure,
and so might be a better monitoring index in women with
GDM. Furthermore, after being described that in premeno-
pausal women, contrary to HgA1c, GA is not influenced by
iron deficiency anaemia or iron deficiency state, the group of
Hashimoto (2008) conducted a trial in 47 Japanese non-dia-
betic pregnant women that revealed once more, that in con-
trast to what happens with HbA1c during pregnancy, GA
levels are not influenced by iron deficiency (Koga et al. 2007).
The same group later reported the same phenomenon in
pregnant women with diabetes (Hashimoto et al. 2010). GA
levels are also unaffected by the dilutional anaemia of preg-
nancy (Hashimoto and Koga 2015). On the other hand, they
can be influenced by conditions that interfere with albumin
metabolism, as nephrotic syndrome or abnormal thyroid
function (Okada et al. 2011; Koga et al. 2009). Research has
also documented that BMI negatively influences GA levels.
One study showed that GA levels decreased with increasing
BMI in 2563 subjects with normal glucose tolerance (Wang
et al. 2012). These findings were further confirmed in type 2
diabetes patients and obese children without diabetes (Koga
et al. 2006; Nishimura et al. 2006). The underlying mechanism
of the decreased GA levels and BMI elevations might be that
obese individuals have a shorter-lived albumin and are in a
state of chronic inflammation (Piva et al. 2013). A study
involving 2118 pregnant women (639 with GDM and 1470
with normal glucose tolerance during pregnancy) that aimed
to assess GA as a potential glycaemic index in managing
GDM also showed that pre-pregnancy BMI was an important
factor influencing GA levels throughout pregnancy (Li et al.
2015).
GA, as a new index of plasma glucose, lacks a widely rec-
ognised reference interval. In 2012, the Japan GA Study
Group conducted a multicentre study involving 574 healthy
Japanese pregnant women to determine the reference inter-
vals of GA and HbA1c as glycaemic control markers. They
also analysed their time courses and influencing factors dur-
ing pregnancy. The reference intervals of GA and HbA1c
throughout normal pregnancy were 11.5–15.7% and
4.5–5.7%, respectively. Furthermore, they noted that GA levels
were decreased in obese pregnant women (BMI 25 Kg/m2)
and in those with proteinuria. Previously, the GA range pro-
posed by Kohzuma et al. (2011) for the American population
was 11.9–15.8% and the Shanghai Diabetes Institute in 2009
recommended that for the Chinese population, the GA range
considered should be 11–17%. We have to admit the possibil-
ity of ethnic differences in GA, as described for HbA1c, but
these ranges are quite similar (Selvin 2016).
Associations between indicators of glycaemic control and
complications in the perinatal period have been explored.
The GA Study Group of the Japanese Society of Diabetes and
Pregnancy, considering the upper limits for HbA1c and GA
(5.7% and 15.7%, respectively) in normal pregnant women
previously mentioned, found that the incidences of neonatal
hypoglycaemia, polycythaemia, respiratory disorder and large-
for-gestational age foetuses was higher in the group of
women with GA of more than 15.7%. On the other hand, it
was reported that there was no significant increase in inci-
dence in the group of women with HbA1c of more than
5.7%, compared with the group of women with HbA1c of
5.7% or less. Although a more accurate judgement should be
made by ROC analysis for different cut-offs, in this case, GA
was superior to HbA1c for prediction of perinatal complica-
tions (Shimizu et al. 2010). Sugawara et al. (2016) retrospect-
ively studied 42 Japanese diabetic mothers (35 with GDM)
and their offspring: mean GA and HbA1c were compared
between mothers of infants with complications (25 cases)
and those without complications (17 controls). GA differed
significantly between the mothers of infants with versus with-
out hypoglycaemia (15.5 ± 1.8 versus 13.8 ± 1.2%, p¼ .001),
respiratory disorders (15.6 ± 1.8 versus 13.9 ± 1.2%, p< .001),
hypocalcaemia (15.7 ± 2.1 versus 14 ± 1.2%, p¼ .004), myocar-
dial hypertrophy (15.2 ± 1.9 versus 13.7 ± 1%, p¼ .007), and
large-for-date status (15.8 ± 1.9 versus 14 ± 1.3%, p¼ .002). By
contrast, HbA1c differed significantly between mothers of
infants with respiratory disorders (6.4 ± 0.8 versus 5.7 ± 0.4%,
p¼ .002), myocardial hypertrophy (6.2 ± 0.7 versus 5.7 ± 0.4%,
p¼ .009), and large-for-date status (6.6 ± 0.8 versus 5.7 ± 0.4%,
p< .001). As for hypoglycaemia (the most frequent complica-
tion of infants of diabetic mothers) and hypocalcaemia,
HbA1c was not significantly different between the two
groups. These results are consistent with the ones reported
by Shimizu et al. (2010): from the point of view of infant
complications, GA is useful for monitoring glycaemic control
in pregnant women with diabetes. A case-control study con-
ducted by Li et al. (2015), including 2118 Chinese pregnant
women (639 with GDM and 1479 controls) found GA level
11.60% to be the best cut-off point for the poor glycaemic
control in GDM—the area under the receiver operating char-
acteristic curve for GA defining a good glycaemic control in
GDM was 0.874 (95% confidence interval 0.811–0.938). Also,
that the risk of birthweight 3500 g and macrosomia
increased significantly with GA levels 13.00% and 12.00%
at 36–38weeks of gestation. Supported by this data, some
authors now suggest the use of GA monitoring once/
3–4weeks as to reduce the frequency of SMBG, thereby
increasing patients’ compliance and lowering health care
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costs (Hashimoto and Koga 2015). Others highlight the
potential clinical utility of the combined information obtained
from SMBG and a marker that accurately reflects variations in
blood glucose levels and mean glycaemic status for short-
term in GDM, as seems to be the case of GA (Li et al. 2015;
Sugawara et al. 2016).
Fructosamine
Serum fructosamine results from the covalent attachment
between a sugar (such as glucose or fructose) to total serum
proteins, primarily albumin, therefore, forming ketoamines. It
provides information on blood glucose levels over the fore-
going 2–4weeks, therefore, being a short-term marker
(Ahmed and Furth 1992; Selvin et al. 2014). Fructosamine
does not seem to be affected by haemoglobin characteristics.
Nevertheless, and unlike HbA1c or GA, it is influenced by
dilutional anaemia, which frequently develops during preg-
nancy. Because 60–70% of serum protein is albumin, condi-
tions that affect the metabolism of the later, as nephritic
syndrome or hyperthyroidism, can also interfere with fructos-
amine levels (Ford et al. 1987; Sako et al. 1989; Constanti
et al. 1992). Its measurement is rapid, inexpensive, precise
and technically simple. Even so, it is not routinely used in
clinical practice. Nonetheless, fructosamine has been pointed
out as a marker of exposure (the period of exposure and glu-
cose variability) and a marker of risk (predictor of what will
occur) in diabetes (Shafi et al. 2013; Parrinello and Selvin
2014; Ribeiro et al. 2016). It is currently used in populations
where HbA1c is thought to inaccurately reflect glycaemia,
including haemoglobinophaties and severe kidney disease
(Shipman et al. 2014). Indeed, fructosamine and GA have
been both cross-sectionally and prospectively associated with
microvascular, macrovascular and all cause morbidity and
mortality in dialysis patients, whereas many studies have
reported no association of HbA1c with these outcomes
(Kumeda et al. 2008; Yamada et al. 2008; Mittman et al. 2010;
Murea et al. 2012).
As glucose tolerance may change very quickly during
pregnancy, fructosamine may have an important role in the
management of GDM. Parfitt et al. (1993) prospectively
studied the relationships between fructosamine, HbA1c and
mean blood glucose, determined from self-blood glucose
monitoring, throughout 16 pregnancies in type 1 diabetic
women. Fructosamine correlated best (Spearman rank) with
mean blood glucose over the previous 2weeks in the first
and the second trimester (0.5) and over the previous week in
the third trimester (0.39). HbA1c correlated best with mean
blood glucose over the previous 8weeks in the first and the
second trimester (0.56), but over the previous 2weeks in the
third trimester (0.524). Also, from the Deming regression
models, fructosamine predicted levels of mean blood glucose
more precisely than HbA1. Authors concluded that an individ-
ual pregnant diabetic woman’s mean blood glucose can be
estimated from her level of fructosamine (more precisely) or
HbA1c. Also that this can be useful to verify self-blood glu-
cose monitoring data.
Few studies exist trying to evaluate associations between
fructosamine levels and neonatal outcomes. A prospective
cohort including 41 pregnant women with diabetes (27 with
GDM) was carried out by Delgado et al. (2011), in which fruc-
tosamine, HbA1c and blood glucose were measured, as to
evaluate the correlation between metabolic control and foetal
macrosomia. No association was demonstrated. The correl-
ation observed between fructosamine and fasting blood glu-
cose (r¼ 0.627, p< .001) was superior to that of HbA1c and
blood glucose (r¼ 0.516, p< .001). Another study conducted
on 91 pregnant women with diabetes mellitus showed that
second trimester plasma levels of fructosamine are related to
the presence or absence of echocardiographic findings of
congenital cardiopathies (Nogueira et al. 2010).
1,5-Anhydroglucitrol (1,5-AG)
1,5-AG is a monosaccharide obtained mainly from dietary
resources that reflects average glycaemia over approximately
the past 2–14 days. The relevance of 1,5-AG to diabetes
stems from the fact that it normally almost all filtered 1,5-
AG to be reabsorbed by the renal tubules. However, when
glycaemia exceeds the renal threshold, at approximately
180mg/dL, glucose competes with 1,5-AG for reabsorption
by the renal tubule, and 1,5-AG is excreted in the urine,
resulting in a drop in circulating 1,5-AG levels in the blood.
As a result, the greater the extent and duration of the blood
glucose above 180mg/dL, the lower will be the 1,5-AG level
in the blood (Buse et al. 2003; Dungan 2008; Yamanouchi
and Akanuma 1994). Soybeans have particularly high levels
of 1,5-AG, and certain foods such as rice, bread and beef
contain modest levels; it is unclear as to what extent dietary
intake may affect circulating 1,5-AG levels and the interpret-
ation of this test (Buse et al. 2003). Because serum 1,5-AG is
influenced by the threshold for urinary glucose excretion as
well, serum 1,5-AG is low in renal glycosuria in which the
threshold decreases. In dialysis or stage 4/5 kidney disease,
the reabsorption of 1,5-AG decreases and, therefore, 1,5-AG
levels are low. In other conditions, such as oxyhyperglycae-
mia, patients receiving long-term hyperalimentation, and
liver cirrhosis, serum 1,5-AG is abnormally low (Emoto et al.
1992; Yamanouchi et al. 1995; Shimizu et al. 1999; Koga
et al. 2011; Kim et al. 2012; Murai et al. 2014). Davison and
Hytten (1975) reported that as during pregnancy the thresh-
old for glucose in the kidney decreases, glycosuria may
appear irrespective of glucose tolerance. Later, Tetsuo et al.
(1990) showed that, because of this mechanism, 1,5-AG dur-
ing pregnancy is low. Therefore, serum 1,5-AG does not
seem to reflect glycaemic control accurately in pregnant
women with diabetes.
Conclusion
HbA1c and self-monitored blood glucose have been the
mainstay of metabolic control in GDM. However, both have
important limitations. New markers of shorter-term glycaemia
are urgently needed, to provide additional or substitute infor-
mation to HbA1c, as metabolic alterations are far more
dynamic than the 2–3month prior period assessed by this
measure and metabolic control is the cornerstone of good
maternal and foetal outcomes.
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GA is an attractive non-traditional marker of glycaemic
control in pregnant women with diabetes: it provides accur-
ate information from the previous 2–3weeks, it is not influ-
enced by iron deficient states common during pregnancy
and it seems to be superior to HbA1c for prediction of some
perinatal complications. However, it is not available in most
clinical settings and still few clinical studies to date have
assessed its validity in GDM management. Large-population
epidemiological studies, representative of the various ethnic
groups are needed. Fructosamine may also be an interesting
marker in GDM and it has the advantage of having an inex-
pensive and technically simple measurement. However, con-
trary to GA, it is affected by dilutional anaemia, which is a
physiologic adaptation during pregnancy and very little data
exists on its association to clinical outcomes.
Randomised clinical trials may help establish construct val-
idity and utility in one or more of this biomarkers and so
help to determine if they can be an efficient and appropriate
alternative to HbA1c in GDM. Moreover, a variety of possible
future applications for these non-traditional biomarkers exists.
As GDM is a heterogeneous condition, spanning from mild
and occasional to a severe and persistent state of hypergly-
caemia (resembling pregestational type 2 diabetes), some
markers may reflect the severity of a woman’s condition, or
they may be more useful in a particular phase of these spec-
trum of dysglycaemic conditions of pregnancy. Also, in add-
ition to assess glycaemic control and to help to predict some
perinatal complications, glycaemic markers may even prove
utility in the aid of treatment choices or add important infor-
mation that can help us to foresee which women are more
likely to become diabetic in the future. These are possibly
some of the paths to the improvement of care in the field of
hyperglycaemic disorders of pregnancy.
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